1. Home
  2. MGRX vs NVNO Comparison

MGRX vs NVNO Comparison

Compare MGRX & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mangoceuticals Inc.

MGRX

Mangoceuticals Inc.

HOLD

Current Price

$0.52

Market Cap

7.1M

Sector

Technology

ML Signal

HOLD

Logo enVVeno Medical Corporation

NVNO

enVVeno Medical Corporation

HOLD

Current Price

$10.39

Market Cap

6.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGRX
NVNO
Founded
2021
1987
Country
United States
United States
Employees
N/A
33
Industry
Computer Software: Prepackaged Software
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
6.8M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
MGRX
NVNO
Price
$0.52
$10.39
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
404.8K
20.6K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
55.17
N/A
EPS
N/A
N/A
Revenue
$456,021.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$140.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$0.30
52 Week High
$2.75
$13.44

Technical Indicators

Market Signals
Indicator
MGRX
NVNO
Relative Strength Index (RSI) 66.94 46.95
Support Level $0.52 $9.93
Resistance Level $0.56 $11.15
Average True Range (ATR) 0.05 0.70
MACD 0.02 -0.09
Stochastic Oscillator 83.96 23.04

Price Performance

Historical Comparison
MGRX
NVNO

About MGRX Mangoceuticals Inc.

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

About NVNO enVVeno Medical Corporation

enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.

Share on Social Networks: